Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

November 23, 2004; 63 (10) Articles

Clinically mild encephalitis/encephalopathy with a reversible splenial lesion

H. Tada, J. Takanashi, A. J. Barkovich, H. Oba, M. Maeda, H. Tsukahara, M. Suzuki, T. Yamamoto, T. Shimono, T. Ichiyama, T. Taoka, O. Sohma, H. Yoshikawa, Y. Kohno
First published November 22, 2004, DOI: https://doi.org/10.1212/01.WNL.0000144274.12174.CB
H. Tada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Takanashi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. J. Barkovich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Oba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Maeda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Tsukahara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Suzuki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Yamamoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Shimono
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Ichiyama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Taoka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O. Sohma
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Yoshikawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y. Kohno
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Clinically mild encephalitis/encephalopathy with a reversible splenial lesion
H. Tada, J. Takanashi, A. J. Barkovich, H. Oba, M. Maeda, H. Tsukahara, M. Suzuki, T. Yamamoto, T. Shimono, T. Ichiyama, T. Taoka, O. Sohma, H. Yoshikawa, Y. Kohno
Neurology Nov 2004, 63 (10) 1854-1858; DOI: 10.1212/01.WNL.0000144274.12174.CB

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
1788

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Objective: To clarify whether patients with clinical diagnoses of encephalitis/encephalopathy with a reversible lesion in the splenium of the corpus callosum (SCC) share common clinical features.

Methods: Possible encephalitis/encephalopathy patients with a reversible isolated SCC lesion on MRI were collected retrospectively. Their clinical, laboratory, and radiologic data were reviewed.

Results: Fifteen encephalitis/encephalopathy patients with a reversible isolated SCC lesion were identified among 22 patients referred for this study. All 15 patients had relatively mild clinical courses. Twelve of the 15 patients had disorders of consciousness. Eight patients had seizures, and three of them received antiepileptic drugs. All 15 patients clinically recovered completely within 1 month (8 patients within a week) after the onset of neurologic symptoms. The SCC lesion was ovoid in six patients; it extended irregularly from the center to the lateral portion of SCC in the other eight patients. Homogeneously reduced diffusion was seen in all seven patients who underwent diffusion-weighted imaging. There was no enhancement in the five patients so examined. The SCC lesion had completely disappeared in all patients at follow-up MRI exams between 3 days and 2 months after the initial MRI (within 1 week in eight patients).

Conclusion: The clinical features among the affected patients were nearly identical, consisting of relatively mild CNS manifestations and complete recovery within 1 month.

MRI is accepted as a more sensitive technique than CT for the diagnosis of encephalitis/encephalopathy and is particularly useful for detecting early changes in the brain. An MRI finding of an ovoid reversible lesion in the central portion of the splenium of the corpus callosum (SCC) without any accompanying lesions has been reported in around 20 patients with epilepsy receiving antiepileptic drugs.1–5⇓⇓⇓⇓ The MR finding is unusual but has been reported in a few patients with encephalitis/encephalopathy caused by various agents such as influenza virus,6 rotavirus,7 and O-157 Escherichia coli.8 These patients had no history of seizures or administration of antiepileptic drugs. These previously reported cases of encephalitis/encephalopathy were clinically mild, and the patients recovered completely. We retrospectively reviewed the clinical, radiologic, and laboratory findings of 15 Japanese patients with encephalitis/encephalopathy with a reversible isolated SCC lesion to clarify whether they share common clinical features and whether their MRI findings are identical to those reported in the literature secondary to epilepsy.1–5⇓⇓⇓⇓

Patients and methods.

Possible encephalitis/encephalopathy patients with a reversible isolated lesion involving the central portion of the SCC on MRI were collected retrospectively by sending out a questionnaire to the members of the Annual Zao Conference on Pediatric Neurology and to some members of the Japanese Society of Pediatric Neurology and Japanese Society of Neuroradiology. We reviewed MR scans and charts of these patients, including information about symptoms, clinical diagnosis, medications, treatments, prognosis, results of CSF analysis, and EEG. The diagnosis of encephalitis has been defined as acute onset of brain dysfunction such as seizures and disorders of consciousness with inflammatory changes such as pleocytosis of CSF. When there was no evidence of inflammatory change, we used the term “encephalopathy.” A reversible isolated SCC lesion was defined, for the purposes of this study, as a lesion involving the central portion of the SCC without any accompanying lesions on the initial MRI, which disappeared on the follow-up study.

Results.

We identified 15 encephalitis/encephalopathy patients with a reversible isolated SCC lesion among the 22 patients whose clinical records and MRI examinations were referred for this study. Three patients were excluded because they had lesions in the white matter or cerebellum as well as in the SCC. Three were excluded because they had no follow-up MRI study. One patient, who was taking oral antiepileptic drugs, had another potential cause for the splenial lesions and was eliminated as well. The clinical records and radiologic examinations of the remaining 15 patients were reviewed by the authors and are the basis of this study. The findings of the 15 patients are summarized in tables 1 and 2⇓.

View this table:
  • View inline
  • View popup

Table 1 Clinical data for encephalitis/encephalopathy with reversible central splenial lesion

View this table:
  • View inline
  • View popup

Table 2 MRI data for patients with encephalitis/encephalopathy with reversible central splenial lesion

The 15 patients (8 male and 7 female; age 2 to 59 years) developed normally until the onset of neurologic symptoms. Fever preceded neurologic symptoms in all 15 patients. Directly causative agents were identified by rapid antigen-detection assay, PCR, positive IgM, or longitudinally increased IgG in 5 of 15 patients. The pathogens included influenza A, mumps virus (two patients), varicella-zoster virus, and adenovirus. The onset of neurologic symptoms ranged from day 1 to 7 of the illness. Eight of the 15 patients had seizures. Other neurologic symptoms included disorders of consciousness (12 patients), vertigo (2 patients), motor deterioration, blindness, ataxia, tremor, and hallucinations. No patient needed mechanical ventilation. Three patients had received antiepileptic drugs (phenobarbital for two patients and phenytoin for another) at the time of MR studies. Analysis of CSF revealed pleocytosis in 6 of 13 examined patients but normal glucose and protein levels. EEG showed slow basic activity characteristic of encephalitis/encephalopathy in 12 of 13 examined patients. Though their treatments were variable (e.g., corticosteroids for five patients and IV IgG administration for three patients), all 15 patients clinically recovered completely within 1 month (8 patients within 1 week after the onset of neurologic symptoms) without sequel.

In 14 of the 15 patients, the initial MR study was performed within 4 days of the onset of neurologic symptoms. On axial images, the lesion was ovoid and in the center of the SCC in six patients (Patients 3, 4, 7, 8, 13, 14) (figure 1) and extended irregularly into the lateral portion of SCC in the other eight patients (figure 2). In Patient 12, a lesion in the central portion of the SCC was detected on sagittal T1- and T2-weighted images (axial T2-weighted image being unavailable). There was no obvious correlation between the shape of SCC lesion and the scan date, neurologic symptoms (presence or absence of seizures, date of complete recovery), or laboratory findings. The SCC lesion was, compared with the surrounding splenium, homogeneously hyperintense on T2-weighted images and isointense to slightly hypointense on T1-weighted images. Homogeneously reduced diffusion (hyperintensity on diffusion-weighted images and low apparent diffusion coefficient [ADC] values) was seen in all seven patients examined by diffusion-weighted imaging. There was no enhancement of the SCC lesion after gadolinium administration in any of the five patients who received contrast material. MRI of Patient 7 showed normal findings at 2 days after the onset of neurologic symptoms but revealed an SCC lesion at 4 days (see figure 1). The SCC abnormalities of all 15 patients completely disappeared at follow-up MRI studies performed 3 days to 2 months after the first abnormal study (within 1 week in 8 of 15 patients). In at least six patients (Patients 1, 5, 8, 9, 13, 15), the SCC lesion disappeared before clinical recovery was complete.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Case 7. MRI on day 5, showing an ovoid lesion in the mid-splenium of the corpus callosum on diffusion-weighted imaging (B) and apparent diffusion coefficient (ADC) map (C) with decreased ADC value and no enhancement on gadolinium-enhanced T1-weighted imaging (A). Follow-up study on day 20 showed no lesion on any sequence (D).

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Case 15. MRI on day 4, showing a lesion extending into the lateral portion of the splenium of the corpus callosum (SCC) on T2- and T1-weighted imaging (A, B) and diffusion-weighted imaging (C). The lesion in the SCC disappeared on all sequences on day 8 (D, E).

Discussion.

Despite different causative agents, the clinical features of the 15 patients with encephalitis/encephalopathy and an isolated reversible SCC lesion were nearly identical, consisting of relatively mild CNS manifestations and complete recovery within 1 month. Thus, we propose that this may represent a new clinicoradiologic syndrome with an excellent prognosis and that MRI is a key study in establishing the diagnosis.

As in any patient with encephalitis/encephalopathy and lesions in the white matter, acute disseminated encephalomyelitis (ADEM) should be considered in the differential diagnosis.9 ADEM is monophasic postinfectious or postvaccinial inflammatory disorder, which is pathologically characterized by an acute perivenous lymphocytic infiltration with confluent demyelination. ADEM presents with seizures, focal neurologic signs, and alteration of consciousness, which develop days to weeks after the onset of presumed viral infections. CSF analysis reveals mild pleocytosis. Corticosteroids are accepted as useful treatment for ADEM, and recovery occurs within weeks.9 In contrast, the patients in this report developed neurologic symptoms quickly after the onset of illness (day 1 to 7) and also recovered completely within 1 month (mostly within 1 week after neurologic manifestations). Directly causative agents were identified in 5 of the 15 patients, suggesting primarily infectious encephalitis/encephalopathy rather than postinfectious. Corticosteroids were not necessary in most of the patients.

MRI in ADEM usually shows multiple foci of T1 and T2 prolongation, typically bilateral and asymmetric, in the subcortical white matter.10 Although the corpus callosum may be involved in ADEM, these patients nearly always have asymmetric callosal lesions in addition to other white matter lesions.11 After contrast agent infusion, the lesions in ADEM will show variable enhancement depending on their acuity. The lesions usually evolve over weeks to months and disappear only after several months, as the imaging evolution of the disease lags behind the clinical evolution. Indeed, the white matter damage may be permanent. The SCC lesions in the patients in this report had no contrast enhancement, and most disappeared completely within 1 week before clinical recovery was complete. The splenial lesions in these patients, therefore, are clinically and radiologically unlikely to represent a manifestation of ADEM.

Other possible differential diagnoses of splenial lesions include ischemia, posterior reversible encephalopathy syndrome, diffuse axonal injury, multiple sclerosis, hydrocephalus, Marchiafava–Bignami disease, lymphoma, and extrapontine myelinolysis.11 These are excluded clinically and radiologically in our patients.

One of the most interesting MRI findings in the patients in this study is that the SCC lesion has reversible, homogeneous reduced diffusion. The reversibility suggests that this finding is distinct from cytotoxic edema seen in cellular energy failure, such as acute infarction, which is nearly always irreversible. We postulate two possible mechanisms for the transiently decreased ADC of the lesions: intramyelinic edema and inflammatory infiltrate. Recently, high signal on diffusion-weighted imaging and decreased ADC values of white matter lesions have been observed in patients with Canavan disease, metachromatic leukodystrophy, and phenylketonuria.12,13⇓ A possible explanation proposed for this phenomenon is intramyelinic edema due to separation of myelin layers.12,13⇓ Interestingly, periventricular T2 abnormalities in phenylketonuria have been shown to be reversible with improvement in metabolic control.13–15⇓⇓ Therefore, the transiently decreased ADC values of the SCC lesion suggest that reversible intramyelinic edema may be the operant factor. A diffusion-weighted imaging study of multiple sclerosis found decreased ADC values in 4 of 28 homogeneously enhancing multiple sclerosis lesions.16 The authors postulated that the influx of inflammatory cells and macromolecules, combined with related cytotoxic edema, might have caused decreased ADC. Thus, the decreased ADC in the splenium may be a result of inflammation. With either cause, intramyelinic edema or inflammation, ADC may return to normal if the cause resolves quickly.

Why is the splenium involved as an isolated site? Although the splenium is the only region where the vertebrobasilar system supplies blood to the corpus callosum (which is primarily supplied by the carotid system),17 the reversibility of the lesions and the absence of any other lesions in vascular distributions make it unlikely that the splenial abnormalities are the result of ischemia. Another possible pathogenesis of the splenial lesions might be related to the presence of elevated inflammatory cytokines, such as interleukin-6,18,19⇓ although the exact mechanism by which the splenium would be involved as an isolated site due to any of the causes is difficult to understand. One might propose that the viral antigens or receptors on the antibodies induced by the antigens have specific affinities for receptors on splenial axons or the myelin sheaths surrounding them, but this is pure speculation.

Recently, an ovoid-shaped reversible splenial lesion has been reported in approximately 20 patients with epilepsy receiving antiepileptic drugs.1–5⇓⇓⇓⇓ Homogeneously reduced diffusion was reported in some examined patients.3–5⇓⇓ Toxic levels or rapid withdrawal of antiepileptic drugs or frequent seizures are presumed to be the cause of the lesion in these patients. The imaging features of the lesions in these epileptic patients are very similar to those in our encephalitis/encephalopathy patients; however, the shape of the lesion is somewhat different. In reported patients and one patient referred to us who was receiving antiepileptic drugs, the SCC lesions were ovoid or round in shape1–5⇓⇓⇓⇓ except for one patient.3 In contrast, the lesions were ovoid in six of our patients and irregularly extended into the lateral portion of the SCC in eight patients with encephalitis/encephalopathy. Among 15 patients with encephalitis/encephalopathy in this study, 7 patients had no seizures, and only 3 of the 8 patients with seizures received antiepileptic drugs. We conclude, therefore, that the lesions in our patients with encephalitis/encephalopathy did not result from seizures or antiepileptic drugs per se, though these two conditions may share the same unknown pathogenesis or have same spectrum.

It is unclear how common this finding might be in patients with mild encephalitis/encephalopathy. Because of the relatively high incidence of influenza-associated encephalitis/encephalopathy in Japan,18,19⇓ we have had the opportunity to obtain brain MRI in 15 children with relatively mild CNS symptoms; however, MRI studies are not commonly obtained in such patients, making it difficult to know how often SCC lesions might be seen in this patient population.

Acknowledgments

The authors thank the patients and their families for their participation. They also thank Z. Kato, MD (Department of Pediatrics, Gifu University School of Medicine, Japan), for advice and Mamiko Ishitobi, MD (Department of Pediatrics, Tohoku University School of Medicine, Miyagi, Japan), and Tomomi Honma, MD (Department of Pediatrics, Yamagata Prefectural Nihonkai Hospital, Japan), for referring patients.

  • Received February 19, 2004.
  • Accepted July 21, 2004.

References

  1. ↵
    Kim SS, Chang K-H, Kim ST, et al. Focal lesion in the splenium of the corpus callosum in epileptic patients: antiepileptic drug toxicity? AJNR Am J Neuroradiol. 1999; 20: 125–129.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Polster T, Hoppe M, Ebner A. Transient lesion in the splenium of the corpus callosum: three further cases in epileptic patients and a pathophysiological hypothesis. J Neurol Neurosurg Psychiatry. 2001; 70: 459–463.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Oster J, Doherty C, Grant PE, Simon M, Cole AJ. Diffusion-weighted imaging abnormalities in the splenium after seizures. Epilepsia. 2003; 44: 852–854.
    OpenUrlCrossRefPubMed
  4. ↵
    Mirsattari SM, Lee DH, Jones MW, Blume WT. Transient lesion in the splenium of the corpus callosum in an epileptic patient. Neurology. 2003; 60: 1838–1841.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Maeda M, Shiroyama T, Tsukahara H, Shimono T, Aoki S, Takeda K. Transient splenial lesion of the corpus callosum associated with antiepileptic drugs: evaluation by diffusion-weighted MR imaging. Eur Radiol. 2003; 13: 1902–1906.
    OpenUrlCrossRefPubMed
  6. ↵
    Takanashi J, Barkovich AJ, Yamaguchi K, Kohno Y. Influenza encephalopathy with a reversible lesion in the splenium of the corpus callosum. AJNR Am J Neuroradiol. 2004; 25: 798–802.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Kobata R, Tsukahara H, Nakai A, et al. Transient MR signal changes in the splenium of the corpus callosum in rotavirus encephalopathy: value of diffusion-weighted imaging. J Comput Assist Tomogr. 2002; 26: 825–828.
    OpenUrlCrossRefPubMed
  8. ↵
    Ogura H, Takaoka M, Kishi M, et al. Reversible MR findings of hemolytic uremic syndrome with mild encephalopathy. AJNR Am J Neuroradiol. 1998; 19: 1144–1145.
    OpenUrlAbstract
  9. ↵
    Dyken PR. Viral diseases of the nervous system. In: Swaiman KF, ed. Pediatric neurology. 2nd ed. St. Louis: Mosby, 1994: 643–688.
  10. ↵
    Barkovich AJ. Toxic and metabolic brain disorders. In: Barkovich AJ, ed. Pediatric neuroimaging. 3rd ed. New York: Lippincott Williams & Wilkins, 2000: 71–156.
  11. ↵
    Friese SA, Bitzer M, Freudenstein D, Voigh K, Kuker W. Classification of acquired lesions of the corpus callosum with MRI. Neuroradiology. 2000; 42: 795–802.
    OpenUrlCrossRefPubMed
  12. ↵
    Engelbrecht V, Scherer A, Rassek M, Witsack HJ, Mödder U. Diffusion-weighted MR imaging in the brain in children: findings in the normal brain and in the brain with white matter disease. Radiology. 2002; 222: 410–418.
    OpenUrlPubMed
  13. ↵
    Micheal D, McGraw P, Lowe MJ, Mathews VP, Hainline BE. Diffusion-weighted imaging of white matter abnormalities in patients with phenylketonuria. AJNR Am J Neuroradiol. 2001; 22: 1583–1586.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Cleary MA, Walter JH, Wraith JE, et al. Magnetic resonance imaging in phenylketonuria: reversal of cerebral white matter change. J Pediatr. 1995; 127: 251–255.
    OpenUrlCrossRefPubMed
  15. ↵
    Thompson AJ, Tillotson S, Smith I, et al. Brain MRI changes in phenylketonuria. Associations with dietary status. Brain. 1993; 116: 811–821.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Roychowdhury S, Maldjian JA, Grossman RI. Multiple sclerosis: comparison of trace apparent diffusion coefficients with MR enhancement pattern of lesions. AJNR Am J Neuroradiol. 2000; 21: 869–874.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Kakou M, Velut S, Destrieux C. Arterial and venous vascularization of the corpus callosum. Neurochirurgie. 1998; 44: S31–S37.
    OpenUrl
  18. ↵
    Morishima T, Togashi T, Yokota S, et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis. 2002; 35: 512–517.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Yoshikawa H, Yamazaki S, Watanabe T, Abe T. Study of influenza-associated encephalitis/encephalopathy in children during the 1997 to 2001 influenza seasons. J Child Neurol. 2001; 16: 885–890.
    OpenUrlAbstract/FREE Full Text

Disputes & Debates: Rapid online correspondence

  • Reply to Shiihara et al and Doherty et al
    • Jun-ichi Takanashi, MD, Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japanjtaka@faculty.chiba-u.jp
    • Hiroko Tada, MD, A. James Barkovich, MD
    Submitted December 27, 2004
  • Clinically mild encephalitis/encephalopathy with a reversible splenial lesion
    • Michael J Doherty, Swedish Neuroscience Institute and the University of Washington Department of Neurology, 801 Broadway Suite 901, Seattle, WA 98122michael.doherty@swedish.org
    • Nate F. Watson, Sumi Jayadev, Ravi S Konchada, Dan K Hallam
    Submitted December 27, 2004
  • Clinically mild encephalitis/encephalopathy with a reversible splenial lesion
    • Takashi Shiihara, Department of Pediatrics, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata, 990-9585, Japanshiihara@med.id.yamagata-u.ac.jp
    • Mitsuhiro Kato, Kiyoshi Hayasaka,
    Submitted December 27, 2004
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Patients and methods.
    • Results.
    • Discussion.
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

  • All Imaging
  • Aphasia
  • Encephalitis

Alert Me

  • Alert me when eletters are published
Neurology: 98 (24)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise